1282733-55-4 Usage
Uses
Used in Pharmaceutical Industry:
(5-bromo-2-chlorophenyl)(2,3-dihydrobenzofuran-5-yl)methanol is used as a potential pharmaceutical candidate for various applications due to its ability to interact with biological targets. Its unique structure and functional groups allow it to engage with specific receptors or enzymes, potentially leading to the development of new drugs with novel mechanisms of action.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (5-bromo-2-chlorophenyl)(2,3-dihydrobenzofuran-5-yl)methanol serves as a valuable compound for studying its interactions with various biological targets. This research can provide insights into the compound's pharmacological activities and help in the design of more effective and targeted therapeutic agents.
Used in Drug Discovery:
(5-bromo-2-chlorophenyl)(2,3-dihydrobenzofuran-5-yl)methanol is used as a starting point in drug discovery efforts. Its unique structural features and potential reactivity make it an attractive candidate for further modification and optimization to develop new drugs with improved efficacy and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 1282733-55-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,2,7,3 and 3 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1282733-55:
(9*1)+(8*2)+(7*8)+(6*2)+(5*7)+(4*3)+(3*3)+(2*5)+(1*5)=164
164 % 10 = 4
So 1282733-55-4 is a valid CAS Registry Number.
1282733-55-4Relevant academic research and scientific papers
C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF
-
, (2013/06/04)
C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed.
